Author:
Adami Giovanni,Fassio Angelo,Rossini Maurizio,Giollo Alessandro,Gatti Davide,Viapiana Ombretta
Publisher
Springer Nature Switzerland
Reference44 articles.
1. Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res. 2017;32(6):1291–6.
2. Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P. Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial. J Bone Miner Res. 2019;34(12):2220–8.
3. Aubry-Rozier B, Liebich G, Stoll D, Gonzalez-Rodriguez E, Hans D, Lamy O. Op0085 can we avoid the loss of bone mineral density one year after denosumab discontinuation? The Reolaus bone project. Ann Rheum Dis. 2019;78(Suppl 2):115.
4. Ban JK, Hao BB, McCarthy L, Guilcher SJT, Cadarette SM. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap. Osteoporos Int. 2019;30(9):1865–72.
5. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, et al. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med. 2005;353(6):555–65.